USC.edu
Are You a Patient?

Caroline Irene Piatek, MD

Clinical Associate Professor of Medicine (Clinician Educator)

Hematology/Oncology Fellowship Program Director

Service Chief for Hematology at LAC+USC

Image of Caroline Irene Piatek, MD
Is this your profile? Click to edit
Email [email protected]
CTSI Profile

Overview

Dr. Carolne Piatek is an Associate Professor in the Jane Anne Nohl Division of Hematology at the Keck School of Medicine of USC. She is currently the fellowship director for the USC/LAC+USC Medical Hematology Fellowship Program. Dr. Piatek’s clinical focus is in non-malignant hematology. Her research interests include immune thrombocytopenia, warm autoimmune hemolytic anemia, cancer-associated thrombosis and paroxysmal nocturnal hemoglobinuria.

After earning her medical degree from Creighton University School of Medicine, Dr. Piatek completed internal medicine residency and hematology/medical oncology fellowship at the University of Southern California.

Awards

  • USC: Medical Oncology Fellow Research Award, 2012
     – 2013
  • American Society of Clinical Oncology: Conquer Cancer Foundation Merit Award, 2014
  • Keck School of Medicine of USC: Hematology Chief Fellow, 2014
     – 2015

Publications

  • Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study. Br J Haematol. 2026 Jun; 208(6):2185-2193.. View in PubMed
  • A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome. Br J Haematol. 2026 May; 208(5):1878-1884.. View in PubMed
  • Thrombotic Thrombocytopenic Purpura in a Patient With Triple-Negative Breast Cancer Treated With PD-L1 Inhibition and Taxane Chemotherapy. Clin Case Rep. 2026 Mar; 14(3):e72247.. View in PubMed
  • Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment. Blood Adv. 2025 Oct 14; 9(19):4936-4945.. View in PubMed
  • Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study. EJHaem. 2025 Aug; 6(4):e70082.. View in PubMed
  • Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. Blood. 2025 Feb 20; 145(8):811-822.. View in PubMed
  • Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2025 Jan; 104(1):81-94.. View in PubMed
  • Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023 Dec; 10(12):e955-e965.. View in PubMed
  • Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD). Am J Hematol. 2024 01; 99(1):79-87.. View in PubMed
  • Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. Adv Ther. 2023 Jan; 40(1):211-232.. View in PubMed

Similar People